HSK39004 clinical trials
How each study uses HSK39004 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the HSK39004 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2025 (4)
| Year | Studies |
|---|---|
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 2 in phase 3
Studies that test HSK39004, phase 3 first.
- Jun 2027A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPDPhase 3 · Haisco Pharmaceutical Group Co., Ltd.
- Sep 2027A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPDPhase 3 · Haisco Pharmaceutical Group Co., Ltd.
- Jul 2027Long-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPDPhase 2 · Haisco Pharmaceutical Group Co., Ltd.
Studies
Open first, then newest update. How each study uses HSK39004 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPDNot yet recruitingPhase 3Haisco Pharmaceutical Group Co., Ltd.NCT07658339Written as HSK39004 Inhalation Suspension
- A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPDRecruitingPhase 3Haisco Pharmaceutical Group Co., Ltd.NCT07583849Written as HSK39004 Dry Powder Inhaler Simulant
- Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)RecruitingPhase 2Haisco Pharmaceutical Group Co., Ltd.NCT07140328Written as HSK39004 Dry Powder Inhaler -0.75mg BID
- Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in COPDNot yet recruitingPhase 3Haisco Pharmaceutical Group Co., Ltd.NCT07634367Written as HSK39004 Inhalation Suspension
- Long-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPDNot yet recruitingPhase 2Haisco Pharmaceutical Group Co., Ltd.NCT07425210Written as HSK39004 Dry Powder Inhaler -0.75mg BID
- Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)Active, not recruitingPhase 2Haisco Pharmaceutical Group Co., Ltd.NCT07108699Written as HSK39004 Dry Powder Inhaler-0.75mg
- A Clinical Study Evaluating the Pharmacokinetics and Pharmacodynamics of HSK39004 Inhalation Suspension in COPD PatientsActive, not recruitingPhase 2Haisco Pharmaceutical Group Co., Ltd.NCT07331402Written as HSK39004 inhalation suspension
- Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HSK39004 Dry Powder InhalationCompletedPhase 1Haisco Pharmaceutical Group Co., Ltd.NCT06971198Written as HSK39004
- Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Primary Efficacy of HSK39004 Suspension for InhalationCompletedPhase 1Haisco Pharmaceutical Group Co., Ltd.NCT06905847Written as HSK39004 in healthy